Dostinex
In brief
- In our pharmacy you can buy dostinex (cabergoline) without a prescription, with delivery across Australia and discreet packaging.
- Dostinex is used to treat hyperprolactinaemia, prolactin-secreting pituitary adenomas (prolactinomas) and related menstrual/fertility problems; it is a long‑acting dopamine D2 receptor agonist that suppresses pituitary prolactin secretion.
- The usual starting dose is 0.5 mg per week (single dose or divided); dose may be increased by 0.5 mg/week as needed, common regimens go up to 1 mg twice weekly and typical maximums are around 2 mg/week for hyperprolactinaemia (higher doses used rarely under specialist supervision).
- Administered orally as a tablet (most commonly 0.5 mg; generics may be 0.25 mg or 1 mg in some markets).
- Effects on serum prolactin can begin within 24–48 hours, though full biochemical response may take 1–2 weeks and clinical improvements (e.g. menses, fertility) may take several weeks to months.
- The drug has a long duration of action (long half‑life) so dosing is typically weekly and prolactin suppression can persist for several days to about a week after a dose; ongoing therapy is often required to maintain effect.
- Avoid alcohol while taking dostinex as it can worsen dizziness, orthostatic hypotension and drowsiness and increase other side effects.
- The most common side effect is nausea; other frequent effects include dizziness, headache, constipation, fatigue and orthostatic hypotension; rare but serious risks include cardiac valve disorders and psychiatric effects such as hallucinations or impulse control problems.
- Would you like to try dostinex without a prescription?
Basic Dostinex Information
- INN (International Nonproprietary Name): Cabergoline
- Brand Names Available In Australia: Dostinex; Cabaser; generics labelled “cabergoline” (local packaging varies)
- ATC Code: G02CB03
- Forms & Dosages: Tablet (oral) 0.5 mg commonly supplied in bottles or blister packs (commonly 2, 8 or 30 tablets); generics may also appear as 0.25 mg or 1 mg formulations in some markets
- Manufacturers In Australia: Pfizer (originator of Dostinex) and numerous generic manufacturers globally; local pharmacy or national drug registry can confirm specific Australian suppliers
- Registration Status In Australia: Not specified in the provided data; patients and clinicians are advised to check the TGA ARTG entry for current registration details
- OTC / Rx Classification: Prescription Only Medicine (Rx)
Critical Warnings & Restrictions — Patient Safety First
Priority Safety Points For Australian Patients (TGA Context)
Cabergoline (INN: Cabergoline) is a prescription-only medicine and must be started under medical supervision.
Registered products are commonly branded as Dostinex (0.5 mg tablets) or supplied as generics.
Patients should check the TGA ARTG entry and PBS eligibility for the specific product supplied in Australia.
Absolute contraindications include uncontrolled hypertension, known hypersensitivity to cabergoline or ergot derivatives, a history of cardiac valvulopathies, and peripartum or postpartum patients with a history of pre‑eclampsia.
Baseline checks are recommended before starting cabergoline.
- Baseline Checklist: blood pressure; echocardiogram if cardiac risk factors present; liver function tests; pregnancy test for women of childbearing age; full medication list; allergy status; pregnancy and lactation status.
Suppression of lactation postpartum is not recommended because of serious risks associated with ergot derivatives.
Ongoing monitoring for psychiatric side effects such as hallucinations and impulse control disorders is essential during treatment.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Elderly patients do not have a standard dose reduction but require increased monitoring for orthostatic hypotension and psychiatric adverse events.
Pregnancy is a relative contraindication and cabergoline should only be used if the benefit justifies the risk.
Cabergoline is contraindicated for breastfeeding.
- Group-Specific Monitoring Actions: For elderly: monitor blood pressure and symptoms of dizziness; for pregnancy: document risk–benefit discussion and consider endocrinology input; for lactation: avoid use and counsel on alternatives; for chronic liver disease: start at a lower dose and monitor LFTs; for renal impairment: monitor clinically.
Patients with chronic liver disease should start at a lower dose and have liver function monitored.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Cabergoline can cause dizziness, syncope, somnolence and orthostatic hypotension which may affect driving and the operation of machinery.
Patients should not drive or operate heavy machinery until they know how cabergoline affects them.
Documenting this advice in patient notes supports medicolegal safety and continuity of care.
- Patient Counselling Checklist: advise not to drive until tolerance is established; avoid sudden position changes; avoid alcohol until effects are known; report any fainting, excessive drowsiness or hallucinations to the prescriber immediately.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking cabergoline?
A: Not until you know how it affects you.
A: Cabergoline can cause dizziness, drowsiness and orthostatic hypotension.
A: Australian road safety law expects drivers to be fit to drive; if symptoms occur, avoid driving and report to your prescriber.
Usage Basics — Names, Classification, Legal Status (Australia)
INN, Brand Names Available In Australia
INN: Cabergoline.
Common brand examples include Dostinex (0.5 mg tablets) and Cabaser in some markets, with generics widely available under the name “cabergoline”.
Packaging commonly seen internationally is 0.5 mg tablets in bottles or blister packs, with typical pack sizes of 2, 8 or 30 tablets depending on supply.
- Dostinex 0.5 mg — tablets commonly supplied in bottles or blister packs.
- Cabaser — higher-dose formulations used in Parkinson’s in some regions (European markets).
- Generics labelled “cabergoline” — packaging varies; ask your local pharmacy for specifics.
Legal Classification (TGA‑Approved, PBS‑Listed)
Cabergoline is classified as prescription-only (Rx) in all markets referenced in the supplied data.
Patients should check the TGA ARTG for current registration details for the exact product sold in Australia.
PBS listings are indication-dependent and may vary by product and approved use, for example prolactinomas and hyperprolactinaemia.
Consult a pharmacist or GP for advice on PBS criteria and whether an authority prescription is needed.
| TGA | PBS |
|---|---|
| Check ARTG entry for product-specific registration details. | Check PBS schedule for subsidy status and authority requirements by indication. |
Dosing Guide — Starting, Titration, And Missed Doses
Standard Regimens & PBS Reference Dosing
Typical starting dose for adult hyperprolactinaemia is 0.5 mg per week, given as a single dose or divided across the week.
Dose may be titrated in increments of 0.5 mg per week as clinically required.
Usual maintenance dosing can be up to 1 mg twice weekly for some patients.
For hyperprolactinaemia the typical maximum dose is 2 mg per week, with higher doses used rarely up to 4.5 mg in exceptional cases.
| Stage | Dose |
|---|---|
| Start | 0.5 mg per week (single or divided) |
| Maintenance | Up to 1 mg twice weekly as needed |
| Typical Max | 2 mg per week (rarely higher up to 4.5 mg) |
Adjustments For Comorbidities
Use in children is not established and is not recommended based on the available data.
Elderly patients have no standard dose reduction but should be closely monitored for adverse effects, particularly if aged over 65.
Patients with liver impairment should start at a lower dose with close monitoring of liver function tests.
There is no standard dose adjustment for kidney impairment, but clinical monitoring is advised.
- Monitoring Steps: check baseline LFTs for hepatic disease; monitor blood pressure and for orthostatic symptoms; review concomitant medicines that may increase sedation or hypotension; consider cardiology input if cardiac history present.
Q&A — “What If I Miss A Dose?”
Q: What should I do if I miss a dose of cabergoline?
A: Take it as soon as you remember unless the next dose is due soon.
A: Do not double the next dose to compensate.
A: If unsure, contact your GP or pharmacist for personalised advice.
Interaction Chart — Food, Alcohol And Common Drug Conflicts
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Alcohol may worsen dizziness, sedation and orthostatic hypotension when combined with cabergoline.
Patients are advised to avoid or limit alcohol until they know how the medicine affects them.
Hydration is important in hot Australian climates to reduce the risk of orthostatic episodes.
- Practical Dietary Advice: avoid heavy alcohol while starting treatment; stay well hydrated in summer; take with food if nausea occurs; moderate caffeine if it worsens palpitations or jitteriness.
Common Drug Interactions
Caution is required when cabergoline is combined with other dopamine agonists or antagonists.
Macrolide antibiotics and other medicines affecting CYP enzymes may alter exposure to cabergoline and require review.
Concurrent antihypertensives may increase the risk of additive hypotension.
Co-administration with other ergot derivatives should be avoided.
Strong CYP3A4 inhibitors or inducers can change levels and may necessitate clinical review.
Psychiatric medicines such as antipsychotics or sedatives warrant careful monitoring for worsening psychiatric or sedative effects.
| Drug | Interaction Type | Action |
|---|---|---|
| Antihypertensives | Additive hypotension | Monitor blood pressure; adjust as needed |
| Macrolide antibiotics | CYP/PK interaction potential | Review with pharmacist; monitor for AEs |
| Antipsychotics/sedatives | Altered psychiatric or sedative effects | Monitor mental state; liaise with prescriber |
User Reports & Trends — Australian Patient Feedback And Safety Signals
Australian patient forums and product reviews often report both benefits and adverse effects with cabergoline use.
Common positive reports include reduction in galactorrhoea, return of menstrual regularity and improved fertility outcomes for some patients.
Common negative reports include nausea, dizziness and fatigue, especially during dose escalation.
Users frequently note rapid symptom relief of breast milk production or galactorrhoea in some cases.
Reporting bias exists and adverse experiences are more likely to be posted online than uneventful courses are to be reported.
Patients should be encouraged to report adverse events to the TGA via the ADR reporting scheme and to inform their prescriber or pharmacist.
- Common Patient-Reported Positives: resolution of galactorrhoea; improved menstrual cycles; improved fertility indicators.
- Common Patient-Reported Negatives: nausea, dizziness, tiredness, occasional psychiatric symptoms.
- When To Seek Help: severe dizziness or fainting; chest pain or breathlessness; new or worsening psychiatric symptoms such as hallucinations or suicidal thoughts.
Access & Purchase Options Across Australia
National Chains And Community Pharmacies
Major pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart typically stock generics and can order branded supplies when available.
Call ahead to confirm stock, particularly for Dostinex 0.5 mg tablets supplied in bottles or blister packs.
- What To Bring When Collecting A Prescription: photo ID; concession card for PBS; current medicines list; the original prescription.
In our online pharmacy, dostinex is available without a prescription, with discreet delivery to Australia in 9-21 days, but patients are reminded that cabergoline is a prescription-only medicine and should be taken only under medical supervision.
Online Pharmacies And Telehealth E‑Prescriptions
E-prescriptions issued via a telehealth consultation are accepted by many Australian online pharmacies for cabergoline dispensing.
Patients should avoid rogue online sellers and only purchase from accredited Australian pharmacies or well-known national chains.
- How To Verify An Online Pharmacy: check for AHPRA registration or an official pharmacy website; look for an Australian address and phone number; confirm a registered pharmacist is contactable.
- Shipping Considerations For Rural Patients: allow extra time for delivery; consider bulk ordering where clinically appropriate; ask about refrigerated or temperature-stable packaging if in extreme climates.
Mechanism & Pharmacology — Simple And Clinical
Simplified Explanation For Patients
Cabergoline is a dopamine D2 receptor agonist that reduces prolactin secretion from the pituitary gland.
Lowering prolactin helps resolve symptoms such as amenorrhoea, galactorrhoea and infertility linked to high prolactin.
Cabergoline can also reduce the size of prolactin-secreting pituitary adenomas over time.
- Quick Facts: INN: Cabergoline; ATC Code: G02CB03; mechanism: D2 agonist; main effect: suppresses prolactin secretion and can shrink prolactinomas.
Clinical Pharmacology Terms For Clinicians
Cabergoline is an ergoline derivative with high affinity for dopamine D2 receptors and a long elimination half-life permitting weekly dosing in many regimens.
At higher cumulative doses, ergoline derivatives have been associated with valvular fibrosis in some studies, which is why cardiac monitoring is recommended for at-risk patients.
- PK Highlights & Monitoring Markers: long half-life enabling weekly dosing; monitor serum prolactin to assess response; consider baseline and interval echocardiography in patients with cardiac risk factors or on high cumulative doses; monitor LFTs where hepatic impairment is present.
Indications & Off‑Label Uses In Australia
TGA‑Approved Indications (Typical Clinical Uses)
Primary uses include treatment of hyperprolactinaemia and prolactin-secreting pituitary adenomas.
Cabergoline treats menstrual and fertility disorders caused by elevated prolactin.
Suppression of lactation postpartum is not recommended due to associated risks.
Any off‑label prescribing should be documented and consented by the patient and prescriber.
Off‑Label Uses In Australian Practice
Off‑label use includes specialist applications such as Parkinson’s disease in some countries at higher doses; these regimens are specialist‑led and require extra monitoring.
- Off‑Label Consent Checklist: document rationale; obtain informed consent; outline extra monitoring such as echocardiography and psychiatric review; involve relevant specialists for high-dose or non-standard indications.
Key Clinical Findings & Recent Study Highlights (2022–2026)
Recent literature continues to support cabergoline as effective at normalising prolactin and reducing adenoma size at low doses for the majority of patients with hyperprolactinaemia.
Evidence links valvular risk primarily to higher cumulative doses seen in Parkinson’s studies rather than the low doses used for hyperprolactinaemia, supporting careful dose selection and cardiac monitoring when indicated.
Quality‑of‑life studies report symptomatic improvement in menstrual regularity and restoration of fertility in many patients treated with cabergoline.
- Study Highlights: high remission rates at low weekly doses for hyperprolactinaemia; common adverse events remain nausea, dizziness and fatigue; valvular risk correlates with cumulative high-dose exposure rather than standard hyperprolactinaemia dosing.
Clinicians are encouraged to reference the latest systematic reviews and local guidelines when deciding on monitoring and dose limits.
Alternatives Matrix — Comparing Dopamine Agonists
PBS‑Listed Alternatives Comparison Table
| Medicine | Dosing Frequency | Efficacy | Side‑Effect Profile | PBS Subsidy Notes |
|---|---|---|---|---|
| Bromocriptine | Daily dosing | Effective for hyperprolactinaemia | More gastrointestinal side effects; lower convenience | Often PBS‑listed; cheaper in many cases |
| Cabergoline | Weekly or twice-weekly dosing | Highly effective; good tolerability | Nausea, dizziness; lower GI upset than bromocriptine | PBS listings vary by indication; check criteria |
| Quinagolide | Daily dosing | Effective alternative in some regions | Different side‑effect spectrum; non-ergot | Availability varies by country |
Pros And Cons Checklist For Choosing Therapy
- Efficacy: both cabergoline and bromocriptine are effective for reducing prolactin.
- Tolerance: cabergoline often better tolerated with less GI upset.
- Fertility Desires: both are suitable; discuss timing of conception with prescriber.
- Cardiovascular Risk: consider echocardiography for those with cardiac history or on high cumulative doses.
- Cost/PBS Access: bromocriptine may be cheaper; check PBS subsidy status with pharmacist.
- Convenience: cabergoline offers weekly dosing which often improves adherence.
Common Questions — Pharmacy Consultation FAQs (Australian Context)
How quickly will my periods return?
Periods commonly return within weeks to months after prolactin normalisation, but timing varies by individual and underlying cause.
Can I try to conceive while on cabergoline?
Many patients conceive successfully on cabergoline once prolactin is controlled; discuss family planning and monitoring with your prescriber.
What side effects are common?
Common side effects include nausea, dizziness, constipation, headache and fatigue; report severe psychiatric symptoms immediately.
Do I need cardiac monitoring?
Baseline cardiac assessment including echocardiography is suggested for patients with cardiac risk factors or those expected to receive high cumulative doses; discuss with your prescriber.
Price & Access Comparison — Pharmacy/Source Table
Price Comparison Table And PBS Subsidy Notes
| Pharmacy / Source | Typical Out‑Of‑Pocket Price Range | PBS Subsidy Applies? |
|---|---|---|
| Chemist Warehouse | Varies by brand; call for current price | Depends on indication and PBS listing |
| Priceline | Varies by brand; call for current price | Depends on indication and PBS listing |
| Independent Pharmacy | Varies; may order specific brands | Depends on indication and PBS listing |
Prices fluctuate and patients should call ahead to confirm current costs and PBS subsidy eligibility.
Access Checklist — Urban Vs Rural Considerations
- Rural Patients: consider telehealth scripts and allow extra time for postal delivery.
- Longer Supply Requests: plan ahead and discuss larger supplies where clinically appropriate.
- Local GP‑Pharmacy Collaboration: useful for continuity in remote areas.
- Cost Sensitivity: discuss generic options and PBS eligibility with the pharmacist.
Registration & Regulation — TGA And PBS Practicalities
TGA Approval And Local Prescribing Rules
Cabergoline is a prescription-only medicine and clinicians should confirm the current TGA ARTG entry for product-specific details and indications.
For higher doses or uncommon indications, document clinical rationale and a monitoring plan in the medical record.
PBS Subsidy Details And Prior Approval Pathways
PBS listings for cabergoline depend on the indication and may require authority prescriptions for specialist indications such as large prolactinomas.
Check the PBS schedule online or speak with a pharmacist to confirm which authority pathways apply.
- Documents For PBS Authority: patient details; clinical indication; supporting investigations such as prolactin level and imaging where required; prescriber details and specialist letters if applicable.
Storage & Handling — Household And Pharmacy Guidance For Australian Climate
Household Storage Advice (Heat/Humidity)
Store cabergoline at 20–25°C and protect from moisture and light.
In hot or humid Australian conditions, keep the medicine in its original packaging in a cool, dry place away from bathrooms and direct sunlight.
- Storage Checklist: do not store in a car glovebox; keep out of reach of children and pets; supervise access; keep in original packaging to preserve stability and expiry information.
Pharmacy Cold‑Chain And Transport Handling
Transport cabergoline in its original packaging and avoid freezing.
Pharmacies should store at recommended room temperature and consider expedited shipping during heatwaves to protect product integrity.
- Pharmacy Shipping Best Practice: use insulated packaging if delivery during extreme heat is expected; communicate expected delivery windows to patients; advise rural customers of possible delays.
Guidelines For Proper Use — Pharmacist Counselling & Patient Actions
Australian Pharmacist Counselling Style (What To Document And Say)
Explain the indication clearly, for example treatment of hyperprolactinaemia or prolactinoma, and the expected timeline for effect.
Advise that serum prolactin often normalises within weeks but may take longer depending on the individual.
Review the dosing schedule and explain weekly dosing specifics if prescribed.
Highlight common side effects including nausea, dizziness and psychiatric symptoms and explain when to seek urgent care for syncope, chest pain or severe psychiatric changes.
- Patient Handout Items To Provide: dosing schedule; common side effects and management tips; emergency signs to watch for; contact details for pharmacist and prescriber; advice on avoiding alcohol until tolerance is known.
- Medical Term Definitions: prolactin — a pituitary hormone involved in lactation and reproductive function; prolactinoma — a pituitary tumour that secretes prolactin.
Refer patients to the TGA adverse event reporting process and local endocrinology referral pathways when specialist care is indicated.
Patient Follow‑Up And Monitoring From PBS And National Health Guidance
Recommend serum prolactin monitoring at baseline, at around 4–6 weeks after starting or changing dose, and then as clinically indicated.
Regular blood pressure checks are suggested, particularly in the elderly and those on antihypertensives.
Consider echocardiography if cardiac risk factors are present or if the patient is expected to receive high cumulative doses.
Document a clear follow-up schedule and clarify the intended duration of therapy.
- Follow‑Up Timeline: baseline bloods and pregnancy test where relevant; prolactin at 4–6 weeks; blood pressure checks within the first few weeks; repeat imaging and endocrine review as indicated.
- Escalation Triggers: persistent high prolactin despite dose escalation; new cardiac symptoms; severe psychiatric changes; intolerable side effects.
Therapy is often continued until serum prolactin is normal for at least six months before considering a trial off treatment, depending on the clinical context.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Darwin | Northern Territory | 14-21 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Albury | New South Wales / Victoria | 14-21 days |
Conclusion And Practical Next Steps
If you have been prescribed cabergoline (dostinex) speak to your GP or pharmacist about baseline checks and the monitoring plan before you start.
Bring a full medicines list and any relevant test results when discussing treatment options.
If you experience worrying side effects such as chest pain, fainting, or new psychiatric symptoms, seek urgent medical attention and inform your prescriber.
For cost or supply questions ask your pharmacist about generic cabergoline options and PBS eligibility.
Report any suspected adverse drug reactions to the TGA and keep a clear record of your treatment dates and doses for ongoing safety monitoring.